Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
NET LOSS	$ (5,403,368)	$ (11,310,001)
Loss from discontinued operations, net of tax	(100,000)	(1,302,553)
Loss from continuing operations	(5,303,368)	(10,007,448)
Adjustments to reconcile loss from continuing operations to net cash used in operating activities:
Stock-based compensation	118,945	1,028,841
Change in fair value of warrant liabilities	(361,137)	(1,377,855)
Change in fair value of derivative liabilities	321,080
Accrued interest on short-term note receivable - Marizyme	(48,082)
(Gain) loss on voluntary conversion of convertible debt	(56,010)	1,077,287
Loss on monthly redemptions of convertible debt into common stock	208,852
Accretion of discount on convertible debt	514,028	1,247,198
Loss on issuance of convertible debt	358,279
Loss on disposal of fixed assets		21,747
Fair value of warrant modification for professional services	12,036
Changes in operating assets and liabilities:
Prepaid expenses and other assets	554,685	(640,105)
Accounts payable	(584,537)	952,269
Accrued expenses and other current liabilities	207,249	443,330
Net cash used in operating activities - continuing operations	(4,057,980)	(7,254,736)
Net cash used in operating activities - discontinued operations		2,622,059
Net cash used in operating activities	(4,057,980)	(4,632,677)
CASH FLOWS FROM INVESTING ACTIVITIES:
Issuance of short-term note receivable - Marizyme	(1,250,000)
Net cash provided by investing activities - discontinued operations	350,000	3,980,541
Net cash provided by (used in) investing activities	(900,000)	3,980,541
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from the issuance of convertible notes payable	1,475,000	(440,000)
Proceeds from issuance of common shares and prefunded warrants in public offering	3,053,348
Net proceeds from issuance of short term debt	2,000,000
Proceeds from warrant exercises	415,981
Payments on short term debt	(2,000,000)
Net cash provided by (used in) financing activities - continuing operations	4,944,329	(440,000)
Net cash provided by (used in) financing activities - discontinued operations
Net cash provided by (used in) financing activities	4,944,329	(440,000)
Net change in cash and cash equivalents	(13,651)	(1,092,136)
Cash and cash equivalents from continuing operations- beginning of period	401,803	3,165,985
Cash and cash equivalents from continuing operations - end of period	388,152	2,073,849
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest	61,020
Taxes	7,864	4,900
NONCASH FINANCING AND INVESTING ACTIVITIES:
Monthly redemptions of convertible debt into common stock	903,329
Voluntary conversion of convertible debt into common stock	735,083	1,112,582
Deemed dividend arising from warrant down-round provision	87,604
Exchange of derivative liability for warrant and convertible debt	675,625
Net transfers to equipment held for lease from inventory		$ 83,271